J.P.Morgan

Frontken Corp

2Q21 earnings in-line; expect sequentially stronger earnings amid semis tightness. Stay OW

FRCB core PATMI grew 25% Y/Y and 14% Q/Q to RM25.4mn in 2Q21 with 1H21 PATMI hitting RM46.5mn, representing 45/43% of JPM/street estimates. As 2H is seasonally stronger, we view the result to be within expectations. We expect FRCB to report sequentially stronger earnings amid the semis upcycle, evidenced by recent commentaries by TSMC, UMC and Intel. Stay OW with PT RM3.80.

- 2Q21 revenue grew 24% Y/Y and 5% Q/Q. FRCB registered sales of RM109mn in 2Q21 (2Q20: RM87.6mn, 1Q21: RM104mn), attributable to greater volume loading especially in its Taiwan plant, where revenue has grown 27% Y/Y. Specifically, FRCB saw higher demand and strong orders from one of its semiconductor customers in advanced node chips.
- Expansion plans on track. FRCB is in the process of setting up a new 118k sqft plant in Taiwan which will potentially double its existing capacity. The plant is expected to be operational by 2H22, in tandem with its key customers' proposed commercial production of 3nm chips.
- Semi supply tightness unlikely to ease before 2023; Positive for FRCB's volume. We believe the semi upcycle should continue into 2022 as UMC's (covered by Gokul Hariharan) recent 2Q21 result suggested strong demand visibility into end-2022. This serves as a read-through to FRCB, as fab's higher utilization rate will mean higher volume loading for FRCB.
- Aligned with our bullish view on key customer TSMC. We remain positive on FRCB's key customer TSMC (covered by Gokul Hariharan) on strong evidence of an accelerated product roadmap, fast-growing customer base in High Performance Computing (HPC) and continued track record of market share gains. We expect TSMC to grow overall revenues at a ~15% CAGR in the next few years, at the high-end of its 10-15% CAGR guidance for 2020-25. As we pointed out on pg.41 of our initiation report, FRCB's revenue growth has a high correlation with TSMC's.
- Reiterate OW as FRCB is a strong proxy for the semis upcycle. Its foundry customers' robust revenue outlook is positive for FRCB. Moreover, semis supply is likely to remain tight as we enter 2022. Stay OW with a PT of RM3.80.

Overweight

FRNK.KL, FRCB MK Price (29 Jul 21): RM3.29

Price Target (Jun-22): RM3.80

Malaysia Semiconductor Equipment

Jeffrey Ng AC

(60-3) 2718 0713

Jeff.Ng@jpmorgan.com

Bloomberg JPMA JNG <GO>

Sean Teo, CFA

(60-3) 2718 0761

sean.teo@jpmorgan.com

JPMorgan Securities (Malaysia) Sdn. Bhd. (18146-X)

Style Exposure

Quant	<u>Current</u>	Hist %Rank (1=Top)						
Factors	%Rank	6M	1Y	3Y	5Y			
Value	83	81	87	39	11			
Growth	15	6	6	15	100			
Momentum	9	23	13	4	97			
Quality	30	13	9	97	92			
Low Vol	85	88	90	95	100			

Sources for: Style Exposure - J.P. Morgan Quantitative and Derivatives Strategy; all other tables are company data and J.P. Morgan estimates.

See page 6 for analyst certification and important disclosures, including non-US analyst disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.



Company Data	
Shares O/S (mn)	1,572
52-week range (RM)	3.97-2.03
Market cap (\$ mn)	1,221
Exchange rate	4.23
Free float(%)	57.4%
3M - Avg daily vol (mn)	6.43
3M - Avg daily val (\$ mn)	4.6
Volatility (90 Day)	40
Index	FBMKLCI - FTSE BURSA
	MALAYSIA KLCI
BBG BUY HOLD SELL	4 0 0

220201110220				٠١٥١٥				
Key Metrics (FYE Dec)								
RM in millions Financial Estimates	FY20A	FY21E	FY22E	FY23E				
				242				
Revenue	368	457	537	649				
Adj. EBITDA	132	166	200	249				
Adj. EBIT	114	146	180	228				
Adj. net income	83	107	131	167				
Adj. EPS	0.08	0.07	0.08	0.11				
BBG EPS	0.05	0.07	0.08	0.10				
Cashflow from operations	120	119	139	168				
FCFF '	114	53	102	131				
Margins and Growth								
Revenue growth	8.4%	24.1%	17.4%	21.0%				
EBITDA margin	35.9%	36.3%	37.3%	38.3%				
EBITDA growth	16.4%	25.4%	20.6%	24.4%				
EBIT margin	30.9%	32.0%	33.5%	35.1%				
Net margin	22.5%	23.4%	24.5%	25.7%				
Adj. EPS growth	18.9%	(14.0%)	22.9%	26.9%				
Ratios		,						
Adj. tax rate	22.7%	22.7%	22.7%	22.7%				
Interest cover	NM	NM	NM	NM				
Net debt/Equity	NM	NM	NM	NM				
Net debt/EBITDA	NM	NM	NM	NM				
ROCE	21.5%	23.8%	25.2%	27.1%				
ROE	20.3%	22.5%	23.7%	25.6%				
Valuation								
FCFF yield	3.3%	1.0%	2.0%	2.5%				
Dividend yield	0.8%	0.7%	0.9%	1.1%				
EV/Revenue	12.0	9.6	8.1	6.6				
EV/EBITDA	33.4	26.6	21.8	17.3				
Adj. P/E	41.6	48.4	39.4	31.0				

Summary Investment Thesis and Valuation

A market leader in providing precision cleaning services in the region, particularly in the semiconductor industry with TSMC making up c.36% of FRCB's FY20 revenue. Investors can gain indirect exposure to front-end semi manufacturing without the associated high capex outlay (9% vs Foundries' average of 22%), in our view.

Valuation

Our Jun-22 PT of RM3.80 is derived by pegging the target P/E of 45x to FY22E EPS. We believe the premium multiple is justifiable for the following reasons: (1) FRCB is the only stock in Bursa Malaysia that has a sizable exposure to the front-end semiconductor space (85% of FY20 revenue) as the rest are more back-end related. We compared the largest front-end player and back-end player in semis manufacturing (TSMC and ASE), and noticed a valuation gap in favor of TSMC (front-end). Therefore, we apply the same logic and conclude that FRCB should trade at a premium to its back-end peers in Malaysia, e.g. Unisem. (2) Greater earnings certainty due to its volume-driven business with anchor customer TSMC, the world's largest foundry.




Table 1: 2Q21 result summary

Rm mm	2Q21	2Q20	YoY	1Q21	QoQ	1H21	1H20	YoY
Revenue	108,625	87,620	24%	103,517	5%	212,142	172,491	23%
Operating Profit	34,469	27,801	24%	34,976	-1%	69,445	52,183	33%
EBITDA	38,233	30,680	25%	37,381	2%	75,614	57,443	32%
PBT	34,536	27,918	24%	35,056	-1%	69,592	52,641	32%
PATMI	24,738	20,329	22%	22,914	8%	47,653	37,336	28%
Core PATMI	25,404	20,278	25%	22,241	14%	47,646	36,614	30%
Margin			Chg in ppt		Chg in ppt			Chg in ppt
Gross profit	31.7%	31.7%	+0.0ppt	33.8%	-2.1ppt	32.7%	30.3%	+2.5ppt
EBITDA	35.2%	35.0%	+0.2ppt	36.1%	-0.9ppt	35.6%	33.3%	+2.3ppt
PBT	31.8%	31.9%	-0.1ppt	33.9%	-2.1ppt	32.8%	30.5%	+2.3ppt
PATMI	23.4%	23.1%	+0.2ppt	21.5%	+1.9ppt	22.5%	21.2%	+1.2ppt

Source: Company data.

Investment Thesis, Valuation and Risks

Frontken Corp (Overweight; Price Target: RM3.80)

Investment Thesis

FRCB is a market leader in providing precision cleaning services in the region, particularly in the semiconductor industry, with TSMC making up c.36% of FRCB's FY20 revenue. Investors can gain indirect exposure to front-end semi manufacturing without the associated high capex outlay (9% vs Foundries' average of 22%), in our view.

Valuation

Our Jun-22 PT of RM3.80 is derived by pegging the target P/E of 45x to FY22E EPS. We believe the premium multiple is justifiable for the following reasons: (1) FRCB is the only stock in Bursa Malaysia that has a sizable exposure to the front-end semiconductor space (85% of FY20 revenue) as the rest are more back-end related. We compared the largest front-end player and back-end player in semis manufacturing (TSMC and ASE), and noticed a valuation gap in favor of TSMC (front-end). Therefore, we apply the same logic and conclude that FRCB should trade at a premium to its back-end peers in Malaysia, e.g. Unisem. (2) Greater earnings certainty due to its volume-driven business with anchor customer TSMC, the world's largest foundry.

Risks to Rating and Price Target

Key risks include 1) Semi inventory correction in 2022. 2) Customer concentration risk as TSMC makes up c.36% of revenue. 3) TSMC's share loss to Samsung given zero exposure to the latter.

Frontken Corp: Summary of Financials

1 TOTICKOTI GOT	P. •	и	a. <u>J</u>	V 1 1	11114	IIOIGIO					
Income Statement	FY19A	FY20A	FY21E	FY22E	FY23E	Cash Flow Statement	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	340	368	457	537	649	Cash flow from operating activities	115	120	119	139	168
COGS	(192)	(203)	(246)	(279)	(327)	o/w Depreciation & amortization	18	18	19	20	21
Gross profit	148	165	212	257	322	o/w Changes in working capital	21	11	(13)	(20)	(29)
SG&A	(26)	(32)	(49)	(60)	(76)						
Adj. EBITDA	114	132	166	200	249	Cash flow from investing activities	(12)	(12)	(65)	(34)	(34)
D&A	(18)	(18)	(19)	(20)	(21)	o/w Capital expenditure	(7)	(8)	(65)	(35)	(35)
Adj. EBIT	96	114	146	180	228	as % of sales	2.1%	2.1%	14.2%	6.5%	5.4%
Net Interest	0	1	1	2	2						
Adj. PBT	96	114	148	181	230	Cash flow from financing activities	(34)	(34)	(37)	(45)	(58)
Tax	(22)	(26)	(34)	(41)	(52)	o/w Dividends paid	(20)	(29)	(37)	(45)	(58)
Minority Interest	(5)	(6)	(7)	(9)	(11)	o/w Shares issued/(repurchased)	0	0	0	0	0
Adj. Net Income	70	83	107	131	167	o/w Net debt issued/(repaid)	(11)	(1)	0	0	0
Reported EPS	0.07	0.08	0.07	0.08	0.11	Net change in cash	71	80	18	59	76
Adj. EPS	0.07	0.08	0.07	0.08	0.11						
						Adj. Free cash flow to firm	108	114	53	102	131
DPS	0.02	0.03	0.02	0.03	0.04	y/y Growth	89.9%	5.5%	(53.1%)	92.1%	28.4%
Payout ratio	27.1%	34.2%	34.5%	34.5%	34.5%						
Shares outstanding	1,048	1,048	1,572	1,572	1,572						
Balance Sheet	FY19A	FY20A	FY21E	FY22E	FY23E	Ratio Analysis	FY19A	FY20A	FY21E	FY22E	FY23E
Cash and cash equivalents	197	290	308	367	443	Gross margin	43.6%	44.9%	46.3%	47.9%	49.6%
Accounts receivable	86	103	118	138	167	EBITDA margin	33.4%	35.9%	36.3%	37.3%	38.3%
Inventories	15	20	21	24	28	EBIT margin	28.2%	30.9%	32.0%	33.5%	35.1%
Other current assets	109	131	146	170	203	Net profit margin	20.5%	22.5%	23.4%	24.5%	25.7%
Current assets	334	443	477	559	668						
PP&E	126	122	171	189	207	ROE	19.8%	20.3%	22.5%	23.7%	25.6%
LT investments	-	-	-	-	-	ROA	14.3%	14.6%	16.2%	17.6%	19.4%
Other non current assets	56	54	51	49	46	ROCE	20.7%	21.5%	23.8%	25.2%	27.1%
Total assets	516	618	698	796	921	SG&A/Sales	7.7%	8.7%	10.7%	11.2%	11.8%
•						Net debt/Equity	NM	NM	NM	NM	NM
Short term borrowings	1	0	0	0	0	Net debt/EBITDA	NM	NM	NM	NM	NM
Payables	17	19	22	25	29						
Other short term liabilities	84	120	120	120	120	Sales/Assets (x)	0.7	0.6	0.7	0.7	8.0
Current liabilities	102	138	141	144	148	Assets/Equity (x)	1.4	1.4	1.4	1.4	1.3
Long-term debt	0	0	0	0	0	Interest cover (x)	NM	NM	NM	NM	NM
Other long term liabilities	15	13	13	13	13	Operating leverage	669.0%	224.8%	118.4%	132.0%	127.5%
Total liabilities	117	151	154	157	161	Tax rate	22.9%	22.7%	22.7%	22.7%	22.7%
Shareholders' equity	377	440	510	596	705	Revenue y/y Growth	3.9%	8.4%	24.1%	17.4%	21.0%
Minority interests	22	27	35	44	55	EBITDA y/y Growth	21.7%	16.4%	25.4%	20.6%	24.4%
Total liabilities & equity	516	618	698	796	921	EPS y/y Growth	34.5%	18.9%	(14.0%)	22.9%	26.9%
BVPS	0.36	0.42	0.32	0.38	0.45	Valuation	FY19A	FY20A	FY21E	FY22E	FY23E
y/y Growth	16.0%	16.7%	(22.7%)	16.9%	18.3%	P/E (x)	49.5	41.6	48.4	39.4	31.0
• •			,,			P/BV (x)	9.1	7.8	10.1	8.7	7.3
						F/DV (X)					
Net debt/(cash)	(196)	(290)	(308)	(367)	(443)	EV/EBITDA (x)	39.7	33.4	26.6	21.8	17.3

Source: Company reports and J.P. Morgan estimates.

Note: RM in millions (except per-share data). Fiscal year ends Dec. o/w - out of which

Other Companies Discussed in This Report (all prices in this report as of market close on 29 July 2021) TSMC(2330.TW/NT\$583.0/OW)

Analyst Certification: The Research Analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an "AC" on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst's personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst's analysis was made in good faith and that the views reflect the Research Analyst's own opinion, without undue influence or intervention.


All authors named within this report are Research Analysts unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

Important Disclosures

- Market Maker/Liquidity Provider: J.P. Morgan is a market maker and/or liquidity provider in the financial instruments of/related to Frontken Corp, TSMC.
- Client: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: TSMC.
- Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as investment banking clients: TSMC.
- Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-investment-banking, securities-related: TSMC.
- Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-securities-related: TSMC.
- Investment Banking Compensation Received: J.P. Morgan has received in the past 12 months compensation for investment banking services from TSMC.
- Potential Investment Banking Compensation: J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from TSMC.
- Non-Investment Banking Compensation Received: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from TSMC.
- Debt Position: J.P. Morgan may hold a position in the debt securities of Frontken Corp, TSMC, if any.

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan—covered companies, and certain non-covered companies, by visiting https://www.jpmm.com/research/disclosures, calling 1-800-477-0406, or e-mailing research.disclosure.inquiries@jpmorgan.com with your request.






 Date
 Rating
 Price (RM)
 Price Target (RM)

 22-Jun-21
 OW
 2.92
 3.8

Source: Bloomberg Finance L.P. and J.P. Morgan; price data adjusted for stock splits and dividends. Initiated coverage Jun 21, 2021. All share prices are as of market close on the previous business day.



	Date	Rating	Price (NT\$)	Price Target (NT\$)
	20-Sep-18	OW	258.0	290
	11-Oct-18	OW	244.0	285
	05-Dec-18	OW	234.0	265
	11-Jan-19	OW	216.0	245
	17-Jan-19	OW	217.5	240
	15-Apr-19	OW	252.0	280
	18-Apr-19	OW	261.5	300
	28-May-19	OW	231.0	275
	18-Jul-19	OW	252.0	280
	25-Sep-19	OW	265.0	320
	18-Oct-19	OW	293.5	350
	17-Jan-20	OW	334.5	370
	13-Mar-20	OW	294.0	335
	01-Apr-20	OW	274.0	325
	09-Jul-20	OW	341.0	355
	17-Jul-20	OW	357.5	375
•	24-Jul-20	OW	381.5	500
	11-Oct-20	OW	453.0	550
	16-Oct-20	OW	453.0	570
	04-Jan-21	OW	530.0	620
	15-Jan-21	OW	592.0	780

The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period.

J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst's (or the analyst's team's) coverage universe.] Not Rated (NR): J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap equity research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those analysts' coverage universe. If it

does not appear in the Important Disclosures section of this report, the certifying analyst's coverage universe can be found on J.P. Morgan's research website, www.ipmorganmarkets.com.

Coverage Universe: Ng, Jeff: Astra Agro Lestari (AALI.JK), BAT (Malaysia) (BATO.KL), Carlsberg Malaysia (CBMS.KL), First Resources (FRLD.SI), Frontken Corp (FRNK.KL), Gamuda (GAMU.KL), Genting Berhad (GENT.KL), Genting Malaysia (GENM.KL), Genting Plantations (GENP.KL), Genting Singapore (GENS.SI), Golden Agri-Resources (GAGR.SI), Greatech Technology (GREA.KL), Hartalega (HTHB.KL), Heineken Malaysia (HEIN.KL), IHH Healthcare (IHHH.KL), IJM (IJMS.KL), IOI (IOIB.KL), KPJ Healthcare (KPJH.KL), Kossan Rubber (KRIB.KL), Kuala Lumpur Kepong (KLKK.KL), MR DIY Group (MRDI.KL), Malaysia Airports (MAHB.KL), Nestle (Malaysia) (NESM.KL), Sime Darby Plantation (SIPL.KL), Sri Trang Gloves (STGT.BK), Supercomnet Technologies (SCTH.KL), Top Glove (TPGC.KL), UWC (UWCB.KL), Wilmar International (WLIL.SI)

J.P. Morgan Equity Research Ratings Distribution, as of July 03, 2021

	Overweight (buy)	Neutral (hold)	Underweight (sell)
IDM CLITE A D IC *	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	()	()
J.P. Morgan Global Equity Research Coverage*	52%	37%	11%
IB clients**	54%	48%	39%
JPMS Equity Research Coverage*	49%	39%	13%
IB clients**	77%	69%	55%

^{*}Please note that the percentages might not add to 100% because of rounding.

For purposes only of FINRA ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at http://www.jpmorganmarkets.com, contact the primary analyst or your J.P. Morgan representative, or email research.disclosure.inquiries@jpmorgan.com. For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, http://www.jpmorganmarkets.com. This report also sets out within it the material underlying assumptions used.

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of http://www.jpmorganmarkets.com where you can also search by analyst name, sector or financial instrument.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

Registration of non-US Analysts: Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of J.P. Morgan Securities LLC, may not be registered as research analysts under FINRA rules, may not be associated persons of J.P. Morgan Securities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

JPMorgan research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

^{**}Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

Options and Futures related research: If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit https://www.theocc.com/components/docs/riskstoc.pdf for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or

http://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf for a copy of the Security Futures Risk Disclosure Statement.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.jpmorgan.com/global/disclosures/interbank offered rates

Private Bank Clients: Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

Legal entity responsible for the production and distribution of research: The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below, this material has been distributed by the legal entity responsible for production. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

Legal Entities Disclosures and Country-/Region-Specific Disclosures:

Argentina: JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina ("BCRA"-Central Bank of Argentina) and Comisión Nacional de Valores ("CNV"- Argentinian Securities Commission" - ALYC y AN Integral N°51). Australia: J.P. Morgan Securities Australia Limited ("JPMSAL") (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. This material is issued and distributed in Australia by or on behalf of JPMSAL only to "wholesale clients" (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting https://www.jpmm.com/research/disclosures. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia's Research Independence Policy which can be found at the following link: J.P. Morgan Australia - Research Independence Policy. Brazil: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com. Canada: J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Investment Industry Regulatory Organization of Canada and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P.Morgan Securities Canada Inc. Chile: Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile. China: J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business. Dubai International Financial Centre (DIFC): JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules. European Economic Area (EEA): Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan AG ("JPM AG"), which is a member of the Frankfurt Stock Exchange, is authorised by the European Central Bank ("ECB") and is regulated by the Federal Financial Supervisory Authority (BaFin). JPM AG is a company incorporated in the Federal Republic of Germany with a registered office at Taunustor 1, 60310 Frankfurt am Main, the Federal Republic of Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions ("ÉEA professional investors"). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. India: J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai - 400098, is registered with the Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with

SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: www.jpmipl.com. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL: IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Indonesia: PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is regulated by the OJK a.k.a. BAPEPAM LK. Korea: J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch. Japan: JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. New Zealand: This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Advisers Act 2008). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan. Philippines: J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. Russia: CB J.P. Morgan Bank International LLC is regulated by the Central Bank of Russia. Singapore: This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 018/04/2020 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) [MCI (P) 052/09/2020], both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material. As at the date of this material, JPMSS is a designated market maker for certain structured warrants listed on the Singapore Exchange where the underlying securities may be the securities discussed in this material. Arising from its role as a designated market maker for such structured warrants, JPMSS may conduct hedging activities in respect of such underlying securities and hold or have an interest in such underlying securities as a result. The updated list of structured warrants for which JPMSS acts as designated market maker may be found on the website of the Singapore Exchange Limited: http://www.sgx.com. South Africa: J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Board, Taiwan: J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. Thailand: This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. UK: Unless specified to the contrary, research is distributed in the UK by J.P. Morgan Securities plc ("JPMS plc") which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. JPMS plc is registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. This material is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 ("the FPO"); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as "UK relevant persons". This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. Research issued by JPMS plc has been prepared in accordance with JPMS ple's policy for prevention and avoidance of conflicts of interest related to the production of Research which can be found at the following link: J.P. Morgan EMEA - Research Independence Policy. U.S.: J.P. Morgan Securities LLC ("JPMS") is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

General: Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. Any data discrepancies in this material could be the result of different calculations and/or adjustments. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

"Other Disclosures" last revised July 17, 2021.

Copyright 2021 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.